GB2398565A — Imatinib preparation and salts
Assigned to Cipla Ltd · Expires 2004-08-25 · 22y expired
What this patent protects
A process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III) <EMI ID=1.1 HE…
USPTO Abstract
A process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III) <EMI ID=1.1 HE=125 WI=140 LX=251 LY=864 TI=CF> <PC>in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt. The present invention is also concerned with imatinib prepared according to the above process. Hydrochloride salts of imatinib in anhydrous or hydrated form are novel compounds.
Drugs covered by this patent
- nilotinib-hydrochloride (Nilotinib Hydrochloride) · Jan Beumer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.